-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
ABT-072
Category | Hepatitis C Virus (HCV) |
CAS | 1132936-00-5 |
Description | ABT-072 is a potent and orally active non-nucleoside HCV NS5B polymerase inhibitor with EC50s of 1 nM and 0.3 nM for HCV GT1a and HCV GT1b, respectively. |
Product Information
Synonyms | (E)-N-(4-(3-(tert-Butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide; Methanesulfonamide, N-[4-[(1E)-2-[5-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-3-(1,1-dimethylethyl)-2-methoxyphenyl]ethenyl]phenyl]-; N-(4-{(E)-2-[5-(2,4-Dioxo-3,4-dihydro-1(2H)-pyrimidinyl)-2-methoxy-3-(2-methyl-2-propanyl)phenyl]vinyl}phenyl)methanesulfonamide |
IUPAC Name | N-[4-[(E)-2-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]ethenyl]phenyl]methanesulfonamide |
Molecular Weight | 469.55 |
Molecular Formula | C24H27N3O5S |
Canonical SMILES | CC(C)(C)C1=CC(=CC(=C1OC)C=CC2=CC=C(C=C2)NS(=O)(=O)C)N3C=CC(=O)NC3=O |
InChI | InChI=1S/C24H27N3O5S/c1-24(2,3)20-15-19(27-13-12-21(28)25-23(27)29)14-17(22(20)32-4)9-6-16-7-10-18(11-8-16)26-33(5,30)31/h6-15,26H,1-5H3,(H,25,28,29)/b9-6+ |
InChIKey | XMZSTQYSBYEENY-RMKNXTFCSA-N |
Purity | ≥95% |
Density | 1.3±0.1 g/cm3 |
Solubility | Soluble in DMSO |
Appearance | Solid Powder |
Storage | Store at -20°C |
Complexity | 879 |
Exact Mass | 469.167145 |
Index Of Refraction | 1.625 |
In Vitro | ABT-072 is a non-nucleoside NS5B polymerase inhibitor with nanomolar potency in vitro against genotype 1a and 1b hepatitis C virus polymerases. |
In Vivo | ABT-072 shows good PK properties, low plasma clearance and high oral bioavailabilit. |
Target | NS5B polymerase |
XLogP3-AA | 3.6 |